GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sotera Health Co (NAS:SHC) » Definitions » Beneish M-Score

Sotera Health Co (Sotera Health Co) Beneish M-Score : -2.01 (As of May. 03, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sotera Health Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.01 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sotera Health Co's Beneish M-Score or its related term are showing as below:

SHC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.72   Med: -2.61   Max: -2.01
Current: -2.01

During the past 6 years, the highest Beneish M-Score of Sotera Health Co was -2.01. The lowest was -2.72. And the median was -2.61.


Sotera Health Co Beneish M-Score Historical Data

The historical data trend for Sotera Health Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sotera Health Co Beneish M-Score Chart

Sotera Health Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -2.72 -2.61 -2.01

Sotera Health Co Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -2.70 -2.10 -2.05 -2.01

Competitive Comparison of Sotera Health Co's Beneish M-Score

For the Diagnostics & Research subindustry, Sotera Health Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sotera Health Co's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sotera Health Co's Beneish M-Score falls into.



Sotera Health Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sotera Health Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0782+0.528 * 1.0089+0.404 * 0.9546+0.892 * 1.0454+0.115 * 1.0992
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9213+4.679 * 0.072481-0.327 * 0.9659
=-2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $176 Mil.
Revenue was 310.239 + 263.177 + 255.282 + 220.59 = $1,049 Mil.
Gross Profit was 180.083 + 145.984 + 139.588 + 111.503 = $577 Mil.
Total Current Assets was $557 Mil.
Total Assets was $3,130 Mil.
Property, Plant and Equipment(Net PPE) was $971 Mil.
Depreciation, Depletion and Amortization(DDA) was $158 Mil.
Selling, General, & Admin. Expense(SGA) was $237 Mil.
Total Current Liabilities was $231 Mil.
Long-Term Debt & Capital Lease Obligation was $2,308 Mil.
Net Income was 38.681 + -13.66 + 23.513 + 2.842 = $51 Mil.
Non Operating Income was 4.299 + -35.001 + 2.009 + 0.906 = $-28 Mil.
Cash Flow from Operations was 113.123 + 41.849 + -336.575 + 33.871 = $-148 Mil.
Total Receivables was $156 Mil.
Revenue was 251.59 + 248.704 + 266.639 + 236.754 = $1,004 Mil.
Gross Profit was 141.72 + 136.013 + 150.396 + 128.875 = $557 Mil.
Total Current Assets was $645 Mil.
Total Assets was $3,118 Mil.
Property, Plant and Equipment(Net PPE) was $801 Mil.
Depreciation, Depletion and Amortization(DDA) was $146 Mil.
Selling, General, & Admin. Expense(SGA) was $246 Mil.
Total Current Liabilities was $792 Mil.
Long-Term Debt & Capital Lease Obligation was $1,826 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(175.519 / 1049.288) / (155.717 / 1003.687)
=0.167274 / 0.155145
=1.0782

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(557.004 / 1003.687) / (577.158 / 1049.288)
=0.554958 / 0.550047
=1.0089

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (557.244 + 970.951) / 3130.42) / (1 - (645.01 + 801.008) / 3117.705)
=0.511824 / 0.536192
=0.9546

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1049.288 / 1003.687
=1.0454

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(145.554 / (145.554 + 801.008)) / (157.925 / (157.925 + 970.951))
=0.153771 / 0.139896
=1.0992

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(236.667 / 1049.288) / (245.714 / 1003.687)
=0.22555 / 0.244811
=0.9213

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2307.554 + 230.654) / 3130.42) / ((1825.647 + 791.567) / 3117.705)
=0.81082 / 0.839468
=0.9659

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(51.376 - -27.787 - -147.732) / 3130.42
=0.072481

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sotera Health Co has a M-score of -2.01 suggests that the company is unlikely to be a manipulator.


Sotera Health Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sotera Health Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sotera Health Co (Sotera Health Co) Business Description

Traded in Other Exchanges
N/A
Address
9100 South Hills Boulevard, Suite 300, Broadview Heights, OH, USA, 44147
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.
Executives
Jonathan M. Lyons officer: Sr. Vice President, CFO 9100 SOUTH HILLS BLVD., SUITE 300, BROADVIEW HEIGHTS OH 44147
Robert Brown Knauss director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Alexander Dimitrief officer: SVP, General Counsel and Sec. GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Michael F Biehl officer: Interim CFO 5885 LANDBROOK DRIVE SUITE 205, CLEVELAND OH 44124
Terry Hammons officer: SVP, GC and Secretary C/O SIMPSON MANUFACTURING CO., INC., 5956 W LAS POSITAS BLVD, PLEASANTON CA 94588
Michael P Rutz officer: President of Sterigenics 8755 WEST HIGGINS ROAD, SUITE 500, CHICAGO IL 60631
Wp Xi Partners, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, 450 LEXINGTON AVENUE NY 10017
Warburg Pincus & Co. director, 10 percent owner 450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147
Gtcr Fund Xi/a Lp director, 10 percent owner 300 NORTH LASALLE STREET, SUITE 5600, CHICAGO IL 60654
Matthew J Klaben officer: SVP, GC and Secretary ONE INFINITY CORPORATE CENTRE DRIVE, SUITE 300, GARFIELD HEIGHTS OH 44125
Petras Michael B. Jr. director, officer: Chairman & CEO 9100 SOUTH HILLS BLVD, SUITE 300, BROADVIEW HEIGHTS OH 44147
Stephanie Geveda director 450 LEXINGTON AVENUE, C/O WARBURG PINCUS LLC, NEW YORK NY 10017
Sean Laurence Cunningham director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Scott J. Leffler officer: CFO and Treasurer C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067

Sotera Health Co (Sotera Health Co) Headlines

From GuruFocus